News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

A 36-week, randomized, double-blind, placebo controlled, parallel group trial to assess the efficacy and safety of PXL065 versus placebo in noncirrhotic, biopsy-proven Nonalcoholic Steatohepatitis (NASH) patients

Study Status:

Study closed

Contact Information:

(956) 362-2378

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

To assess the effect of 3 doses of PXL065 (7.5 mg QD, 15 mg QD and 22.5 mg QD) versus placebo on liver fat content (LFC) in NASH patients after 36 weeks of treatment


Principal Investigator
Marcel B. Twahirwa, MD
John Rodriguez
Type of Trial
© 2024 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram